Social cost of retinal blindness in US will be billions of dollars by 2020

FORT LAUDERDALE, Fla. — The direct, indirect, and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy is estimated to cost the U.S. approximately $21 billion by 2020, according to a speaker here.
“Age-related macular degeneration will constitute the lion’s share of this amount with a little over $16 billion. Diabetic retinopathy will be about $4.5 billion,” Andrew A. Moshfeghi, MD, MBA, said at Retina World Congress.
If management of neovascular age-related macular degeneration (nAMD),

Full Story →